Sentence examples for potency for each from inspiring English sources

Isobolographic and dose-addition analysis were used to statistically compare the experimentally determined potency for each mixture (zmix) with predicted additive potency (zadd).

ATP and UTP are full agonists for both rat receptors, and each ligand has similar potency for each receptor (Wildman et al., 2003).

Intriguingly, the potency of aripiprazole for the potentiation of AA release was significantly higher than that for MAPK phosphorylation, while the relative potency for each of these downstream effectors was comparable for other D2R ligands, including dopamine and quinpirole.

Therefore, the optimization of vaccine potency for each form of the vaccine before we perform a head-to-head comparison in the future will generate a more comprehensive picture of the efficacy of the different vaccination approaches compared to HPV pseudovirions.

This paper presents two types of information from the Carcinogenic Potency Database (CPDB): (a) the sixth chronological plot of analyses of long-term carcinogenesis bioassays, and (b) an index to chemicals in all six plots, including a summary compendium of positivity and potency for each chemical (Appendix 14).

In addition to assessing breast cancer risk associated with oestrogen and progestin types, we also evaluated oestrogen and progestin potencies for each pill preparation.

It should be pointed out that when we extracted the potency value for each unique active compound, we also applied some criteria: (1) if the same compound has multiple potency values with the same log order, we obtained the mean value of them as the final potency value; (2) if the same compound has multiple potency values with the difference of more than one log order, we removed such compounds.

Potency ratios for each agonist are the reciprocals of the dose ratios (i.e. equivalent to saying that each agonist is x times more potent than ACh).

The potency obtained for each RTKI from this analysis was similar to those obtained in binding studies using purified VEGFR2 kinase domains.

This method for summarizing exposure to the 24 MGC was chosen over a simple summation because the range of concentrations among these compounds varied dramatically and because the potency factor for each unit concentration was not assumed to be similar across the compounds.

Viral vectors have undergone extensive preclinical assessment for a wide spectrum of diseases and have been tested in numerous clinical trials, and these studies have revealed hierarchies of potency for individual vectors and each viral vector has its own advantages, limitations and range of applications (reviewed in Rollier et al, 2011).